Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $201,191.96 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 4,841 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $201,191.96. Following the transaction, the chief executive officer now owns 603,886 shares in the company, valued at approximately $25,097,502.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Twist Bioscience Trading Down 0.3 %

NASDAQ TWST opened at $45.40 on Friday. The company has a fifty day simple moving average of $43.69 and a two-hundred day simple moving average of $45.54. The stock has a market cap of $2.66 billion, a P/E ratio of -11.88 and a beta of 1.78. Twist Bioscience Co. has a 12-month low of $15.85 and a 12-month high of $60.90.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TWST. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Barclays dropped their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans purchased a new position in shares of Twist Bioscience in the third quarter worth $43,992,000. Point72 Asset Management L.P. raised its holdings in shares of Twist Bioscience by 1,021.8% in the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after buying an additional 613,057 shares during the last quarter. Fred Alger Management LLC raised its holdings in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after buying an additional 575,080 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Twist Bioscience by 1.8% in the third quarter. New York State Common Retirement Fund now owns 482,606 shares of the company’s stock worth $21,804,000 after buying an additional 8,529 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its holdings in shares of Twist Bioscience by 63.0% in the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock worth $19,152,000 after buying an additional 150,260 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.